Skip to main navigation Skip to search Skip to main content

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)

  • Marta Palafox
  • , Laia Monserrat
  • , Meritxell Bellet
  • , Guillermo Villacampa
  • , Abel Gonzalez-Perez
  • , Mafalda Oliveira
  • , Fara Brasó-Maristany
  • , Nusaibah Ibrahimi
  • , Srinivasaraghavan Kannan
  • , Leonardo Mina
  • , Maria Teresa Herrera-Abreu
  • , Andreu Òdena
  • , Mònica Sánchez-Guixé
  • , Marta Capelán
  • , Analía Azaro
  • , Alejandra Bruna
  • , Olga Rodríguez
  • , Marta Guzmán
  • , Judit Grueso
  • , Cristina Viaplana
    • Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra*
*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Nursing and Health Professions

Veterinary Science and Veterinary Medicine